Unlocking the Potential of Ribosomal Protein L13a Pseudogene 22 as a Drug Target or Biomarker

Target Name: RPL13AP22

NCBI ID: G441632

RPL13AP22

Other Name(s): ribosomal protein L13a pseudogene 22 | RPL13A_9_1223 | Ribosomal protein L13a pseudogene 22

Unlocking the Potential of Ribosomal Protein L13a Pseudogene 22 as a Drug Target or Biomarker

Introduction

Ribosomal protein (RP) L13a pseudogene 22 (RP L13a 22) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. It is a key component of the ribosome, the site of protein synthesis, and its levels are regulated by various factors, including DNA replication, transcription, and post-transcriptional modification. RP L13a 22 has been identified as a potential drug target and biomarker due to its unique biology and expressed levels in various tissues.

Dise帽o y descripci贸n

RP L13a 22 is a small non-coding RNA molecule that is expressed in various tissues and cells, including muscle, heart, brain, and cancer cells. It is composed of 22 amino acids and has a calculated molecular weight of 23.9 kDa. RP L13a 22 is highly expressed in muscle and heart tissues, and its levels are also elevated in cancer cells compared to healthy tissue.

RP L13a 22 functions as a key regulator of gene expression by binding to specific binding sites on target genes. It plays a role in the regulation of protein synthesis, cell growth, and apoptosis. RP L13a 22 has been shown to interact with various protein partners , including the transcription factor, activator protein 1 (TAP1), which is critical for cell survival and proliferation.

RP L13a 22 has also been shown to play a role in the regulation of DNA replication and transcription. It has been shown to interact with the DNA-binding protein, p53, and enhance its transcriptional activity. This interaction between RP L13a 22 and p53 suggests a potential role for RP L13a 22 in the regulation of DNA replication and gene expression.

RP L13a 22 has also been shown to be involved in the regulation of cell apoptosis. It has been shown to play a role in the regulation of cell apoptosis and has been shown to interact with the protein, Bcl-2. This interaction between RP L13a 22 and Bcl-2 suggest a potential role for RP L13a 22 in the regulation of cell apoptosis.

RP L13a 22 has been identified as a potential drug target due to its unique biology and its expressed levels in various tissues. Studies have shown that inhibiting RP L13a 22 can lead to a variety of cellular and molecular changes, including increased cell proliferation, decreased cell apoptosis, and altered protein synthesis.

RP L13a 22 has also been shown to be a potential biomarker for various diseases, including cancer, heart disease, and neurodegenerative diseases. Studies have shown that RP L13a 22 is overexpressed in various cancer tissues and that inhibiting RP L13a 22 has been shown to be effective in reducing cancer cell proliferation.

Conclusion

RP L13a 22 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. Its unique biology and expressed levels in various tissues make it a potential drug target and biomarker. Studies have shown that inhibiting RP L13a 22 can lead to a variety of cellular and molecular changes, including increased cell proliferation, decreased cell apoptosis, and altered protein synthesis. These findings suggest that RP L13a 22 may be a valuable drug target or biomarker for various diseases. Further research is needed to fully understand the biology of RP L13a 22 and its potential as a drug

Protein Name: Ribosomal Protein L13a Pseudogene 22

The "RPL13AP22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13AP22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets